Health

#52026XC03327EU medicinal product marketing authorisations for May 2026

🇪🇺European Union··Other·Low Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

The notice records EU decisions made in May 2026 on marketing authorisations for medicinal products. It lists new authorisations for products including Bysumlog, Joenja, ADSTILADRIN, Bopediat, IMDYLLTRA and ZEPZELCA, plus routine modifications to existing authorisations. The practical impact is mainly for pharmaceutical companies, healthcare providers, distributors and regulators. Companies named in the notice can rely on the listed EU register entries, while market participants should update product, regulatory and pharmacovigilance records where relevant.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Lists six new EU marketing authorisations for medicinal products decided in May 2026
  • Records modifications to existing marketing authorisations for previously approved products
  • Provides register numbers, authorisation holders, product forms, ATC codes and notification dates

Affected Parties

Pharmaceutical companiesHealthcare providers+2 more…

Tags

medicinal products,marketing authorisation,pharmaceutical regulation

More from European Union

EU Marketing Authorisation Decisions for Medicinal Products, January-April 2026

EU Court Limits France’s Rules on Doctors Charging Non-Standard Fees

EU correction to the Estonian text of plastic food-contact materials rules